secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001140361-25-044110
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026
------------------------------------------------------------------------

- HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.
- BioCryst expects the merger with Astria Therapeutics to close in Q1 2026.
- Remaining conditions still required; deal previously announced.
- Removal of antitrust risk is a positive step toward closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000114036125044110/0001140361-25-044110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000114036125044110/ef20060538_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-044110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer